Renaissance Technologies’s Ovid Therapeutics OVID Stock Holding History

Renaissance Technologies’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$284K	Sell	105,500 -998,800	-90%	-$2.58M	﹤0.01%	2793
2026 Q1	$2.45M	Sell	1,104,300 -380,178	-26%	-$680K	﹤0.01%	1788
2025 Q4	$2.42M	Sell	1,484,478 -533,546	-26%	-$822K	﹤0.01%	1746
2025 Q3	$2.62M	Sell	2,018,024 -77,285	-4%	-$67K	﹤0.01%	1900
2025 Q2	$691K	Buy	2,095,309 +1,071,509	+105%	+$323K	﹤0.01%	2678
2025 Q1	$319K	Buy	1,023,800 +916,100	+851%	+$563K	﹤0.01%	2911
2024 Q4	$101K	Buy	107,700 +63,200	+142%	+$70.7K	﹤0.01%	3285
2024 Q3	$52.5K	Sell	44,500 -96,700	-68%	-$101K	﹤0.01%	3337
2024 Q2	$109K	Sell	141,200 -15,600	-10%	-$43.4K	﹤0.01%	3168
2024 Q1	$478K	Buy	156,800 +105,600	+206%	+$353K	﹤0.01%	2884
2023 Q4	$165K	Sell	51,200 -29,600	-37%	-$101K	﹤0.01%	3191
2023 Q3	$310K	Sell	80,800 -33,900	-30%	-$122K	﹤0.01%	2918
2023 Q2	$376K	Sell	114,700 -5,900	-5%	-$20K	﹤0.01%	3022
2023 Q1	$311K	Buy	120,600 +800	+0.7%	+$1.9K	﹤0.01%	3103
2022 Q4	$223K	Buy	119,800 +1,000	+0.8%	+$1.7K	﹤0.01%	3368
2022 Q3	$219K	Sell	118,800 -5,000	-4%	-$10.5K	﹤0.01%	3350
2022 Q2	$266K	Buy	123,800 +39,000	+46%	+$94.2K	﹤0.01%	3521
2022 Q1	$266K	Buy	84,800 +26,200	+45%	+$82.4K	﹤0.01%	3525
2021 Q4	$188K	Buy	58,600 +24,100	+70%	+$82.6K	﹤0.01%	3531
2021 Q3	$116K	Buy	+34,500	New	+$126K	﹤0.01%	3296
2021 Q1	–	Sell	-710,507	Closed	-$1.64M	–	3601
2020 Q4	$1.64M	Buy	+710,507	New	+$3.31M	﹤0.01%	2244
2020 Q3	–	Sell	-624,109	Closed	-$4.6M	–	3595
2020 Q2	$4.6M	Sell	624,109 -228,734	-27%	-$1.07M	﹤0.01%	1695
2020 Q1	$2.54M	Sell	852,843 -231,866	-21%	-$781K	﹤0.01%	1936
2019 Q4	$4.5M	Buy	1,084,709 +497,984	+85%	+$1.57M	﹤0.01%	1914
2019 Q3	$1.9M	Buy	586,725 +115,116	+24%	+$262K	﹤0.01%	2307
2019 Q2	$872K	Buy	471,609 +108,392	+30%	+$194K	﹤0.01%	2743
2019 Q1	$643K	Buy	363,217 +308,117	+559%	+$771K	﹤0.01%	2848
2018 Q4	$133K	Buy	+55,100	New	+$251K	﹤0.01%	3196

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies's OVID Position: Q2 2026 in Review

Renaissance Technologies reduced its Ovid Therapeutics (OVID) stake by 90% in Q2 2026, selling an estimated $2.58M and leaving 105,500 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Renaissance Technologies first reported a position in OVID in Q4 2018 and has held it in 28 quarters since. The position peaked at $4.6M in Q2 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Renaissance Technologies held 105,500 shares of Ovid Therapeutics worth $284K as of Q2 2026.
Renaissance Technologies sold 998,800 Ovid Therapeutics shares in Q2 2026, an estimated $2.58M.
Ovid Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2793 holding.
Renaissance Technologies first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 28 quarters since.
Renaissance Technologies's Ovid Therapeutics position peaked at $4.6M in Q2 2020.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.